Want to see CHRN full AI Analyst Report?
Top Page
ChronoScale
(NASDAQ:CHRN)
Select Model
Select Model
Rating:57Neutral
Price Target:
$23.50
▲(131.53% Upside)
Action:Reiterated
Date:06/27/26
The score is held back primarily by weak financial performance—large ongoing losses, persistent cash burn, and a sharply reduced equity cushion. Technicals provide meaningful support via a strong multi-timeframe uptrend with positive momentum. Valuation is constrained by negative earnings and no dividend support, while corporate events are mixed: improved liquidity via a related-party credit line is offset by governance concerns and uncertainty around divestiture-related charges.
Positive Factors
Stable gross margins
A mid-50s gross margin is a durable sign of healthy product-level economics. It gives the company structural room to cover variable costs and offers leverage to improve profitability as revenue stabilizes or grows, making margin recovery feasible if operating spend is aligned.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicates the business cannot self-fund operations. Ongoing cash consumption forces reliance on external financing or related-party support, raises dilution or leverage risk, and constrains the company's ability to invest in product development or sales capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable gross margins
A mid-50s gross margin is a durable sign of healthy product-level economics. It gives the company structural room to cover variable costs and offers leverage to improve profitability as revenue stabilizes or grows, making margin recovery feasible if operating spend is aligned.
Read all positive factors
ChronoScale Key Performance Indicators (KPIs)
ChronoScale (CHRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.18B
Dividend YieldN/A
Average Volume (3M)398.58K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth-34.08%
EPS Growth26.18%
CountryUS
Employees55
SectorTechnology
Sector Strength88
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-5.39
Shares Outstanding143,093,380
10 Day Avg. Volume392,348
30 Day Avg. Volume398,579
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.32
Price to Sales (P/S)1.64
P/FCF Ratio-1.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue2.47
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda-2.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$19.38M
ChronoScale Business Overview & Revenue Model
Company Description
Ekso Bionics Holdings, Inc., which began operations on January 30, 2012, and is headquartered in San Rafael, California, specializes in developing, refining, and marketing advanced exoskeleton technology. These innovative systems are currently app...
ChronoScale Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
14
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
ChronoScale Technical Analysis
Positive
10.15
Price Trends
16.37
Positive
13.39
Positive
9.52
Positive
Market Momentum
1.97
Negative
58.55
Neutral
47.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRN, the sentiment is Positive. The current price of 10.15 is below the 20-day moving average (MA) of 20.36, below the 50-day MA of 16.37, and above the 200-day MA of 9.52, indicating a bullish trend. The MACD of 1.97 indicates Negative momentum. The RSI at 58.55 is Neutral, neither overbought nor oversold. The STOCH value of 47.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRN.
ChronoScale Risk Analysis
ChronoScale disclosed 39 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ChronoScale Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | $3.18B | -2.65 | -177.40% | ― | -34.08% | 26.18% | |
49 Neutral | $27.24M | -2.78 | -73.04% | ― | -6.42% | 83.35% | |
45 Neutral | $28.28M | -5.74 | -166.28% | ― | 3.37% | 15.78% | |
41 Neutral | $5.02M | -0.47 | -74.10% | ― | 74.57% | 60.81% |
* Technology Sector Average
CHRN
ChronoScale
22.86
19.47
574.34%
HBIO
Harvard Bioscience
6.13
1.64
36.63%
MLSS
Milestone Scientific
0.32
-0.32
-49.84%
LUCY
Innovative Eyewear, Inc.
0.82
-1.29
-61.09%
ChronoScale Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
ChronoScale Secures $100 Million Related-Party Credit Line
Positive
Jun 26, 2026
On June 26, 2026, ChronoScale Corporation entered into an unsecured demand grid promissory note with Applied Digital Corporation, establishing a flexible line of credit of up to $100 million, adjusted for any credit support previously provided. Th...
Business Operations and StrategyM&A Transactions
ChronoScale Divests Ekso Bionics to Refocus on Cloud
Negative
Jun 4, 2026
On May 29, 2026, ChronoScale Corporation’s board approved a plan to divest its wholly owned subsidiary Ekso Bionics, Inc., which had not previously been disclosed as held for sale. The move marks a strategic pivot to focus the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.